Mushrooms
Chaga
Chaga is a mushroom supplement. People may take it in connection with digestion, mood, memory, present-moment awareness, and allergy symptoms, while research has also explored possible relevance to Diabetes Type 2, Kidney Disease (General), and Obesity.
Chaga is explored across allergy symptom relief, digestion improvement, and emotional regulation improvement.
Overview
Chaga is a mushroom supplement. People may take it in connection with digestion, mood, memory, present-moment awareness, and allergy symptoms, while research has also explored possible relevance to Diabetes Type 2, Kidney Disease (General), and Obesity.
The overall evidence picture is insufficient. The available literature does not establish Chaga as effective for these uses, and the reported probabilities for the listed effects and indications are low. Much of the support comes from animal research or anecdotal reports rather than studies that directly evaluate outcomes in people.
This limits how confidently findings can be applied to human use. Results from animal studies may help identify topics for further investigation, but they do not demonstrate that the same effects occur in people. Anecdotal reports can describe individual experiences but cannot determine whether Chaga caused an outcome or whether it is likely to work consistently. The strongest study design represented is a case report, so the current evidence should be viewed as preliminary rather than settled.
Barely researched: 87 studies. Last checked Oct 8, 2026.
- 0
- human evidence
- 0
- eligible
- 12
- unclassified
- 15
- animal / null result
Best-evidenced uses
- Antioxidant Protection EnhancementLow · Reference knowledge
- Kidney Disease (General)Low · Animal research
- Blood Glucose Level SupportLow · Animal research
- 87
- Studies
Evidence checked Oct 8, 2026 · newest study 2026
The text on this page was written before the latest evidence check. The tables and numbers are up to date.
- D
- 87
318 community reports across 5 platforms
Coverage
- Effects
- 19
- Helps with
- 8
- Side effects
- 9
- Interactions
- 22
How to read the evidence
Evidence tier — overall strength of the evidence for the whole compound
- StrongWell established — backed by strong, consistent human research.
- ModerateSome genuine support, but mostly from small or lower-quality studies. Promising, not proven.
- PreliminaryEarly-stage evidence — a promising hypothesis, not an established effect yet.
- LimitedVery limited evidence — treat this as a hypothesis, not proof.
- InsufficientNot enough good evidence to draw conclusions yet.
Certainty — how sure we can be that the effect is real
- Very highVery sure — strong, consistent evidence
- HighFairly sure — consistent evidence from good studies
- MediumModerately sure — new studies could change this
- LowNot sure — little or mixed evidence
- Very lowVery unsure — almost no usable evidence
Source — where the data comes from
- Meta-analysisPooled analysis of many trials — the strongest evidence
- RCTRandomized controlled trial — a strong human study design
- ClinicalA human clinical study
- Reference knowledgeFrom general health-science or pharmacology references, not a study of this exact claim
- Animal researchStudied in animals, not humans
- Community reportsAggregated user reports — anecdotal signal, not evidence
- TheoreticalMechanism-based reasoning, not yet tested
Study grade — quality of each underlying study (A best, D weakest)
- AHigh-quality — strong, consistent human trials
- BGood — solid evidence with some limitations
- CModerate — limited, small, or mixed-quality studies
- DWeak — preliminary, indirect, or animal-only
Confidence — how strongly the sources back a finding
A 0–100 score from study quality and agreement
Most supplement evidence is graded C–D. Read it as preliminary signal, not proof.
These are research findings, not promises. A supplement does not replace medical treatment, and taking more does not work better.
What does research say?
None of these claims has good evidence yet. Best evidence first.
19 claims:2 not enough evidence17 not tested in people
Antioxidant Protection EnhancementNot enough evidence
Too few or too small studies to know if it works.
All 2 studies with a clear result found a benefit. Amount studied: 1–3 g daily of dried extract.
In laboratory testing, IO–AgNPs and MIO–AgNPs significantly outperformed native I. obliquus extract. This result comes from in vitro testing rather than a clinical outcome in people.
Open the Antioxidant Protection Enhancement pageDNA Damage ProtectionNot enough evidence
Too few or too small studies to know if it works.
The one study found a benefit.
Open the DNA Damage Protection pageImmune System SupportNot tested in people
Only tested in animals, cells or theory. Results like these often do not carry over to people.
All 2 studies with a clear result found a benefit. Strongest study: an animal study. Amount studied: 1–2 g daily, for Temporal monitoring 0 to 35 days post-inoculation.
Chaga contains beta-glucans and polysaccharides described as modulating immune cell activity and cytokine production. It is also described as an immunomodulatory medicinal mushroom with beta-glucans that enhance immune function.
Open the Immune System Support pageCognitive Function ImprovementNot tested in people
Only tested in animals, cells or theory. Results like these often do not carry over to people.
The one study found a benefit. Strongest study: an animal study.
Open the Cognitive Function Improvement pageBlood Glucose Level SupportNot tested in people
Only tested in animals, cells or theory. Results like these often do not carry over to people.
7 of 8 studies found a benefit; 1 found none. Strongest study: an animal study. Studied for 21 days.
Open the Blood Glucose Level Support pageCholesterol Level ReductionNot tested in people
Only tested in animals, cells or theory. Results like these often do not carry over to people.
All 7 studies with a clear result found a benefit. Strongest study: an animal study. Studied for 12 weeks.
In animal models, total cholesterol was lower with IOPH and IOPM than in the model group. HIOP produced a 40.0% reduction versus HFD.
Open the Cholesterol Level Reduction pageKidney Health SupportNot tested in people
Only tested in animals, cells or theory. Results like these often do not carry over to people.
4 of 5 studies found a benefit; 1 found none. Strongest study: an animal study. Studied for 12 weeks.
At 17 weeks in an animal model of diabetic kidney disease, both doses significantly reduced SCr versus the DKD model; Chaga100 returned SCr to levels not different from the normal control. Kidney-related measures also significantly improved with IO_L and IO_H versus ORG and were not different from CON.
Open the Kidney Health Support pageInsulin Sensitivity ImprovementNot tested in people
Only tested in animals, cells or theory. Results like these often do not carry over to people.
All 5 studies with a clear result found a benefit. Strongest study: an animal study. Studied for 8 weeks.
Open the Insulin Sensitivity Improvement page
Only reported by users, not studied: Mood Improvement, Physical Energy Increase, Concentration Improvement, Brain Fog Reduction, Anxiety Reduction, Sleep Quality Improvement, and 1 more.
Also studied in people with 8 health conditions
How strong the evidence is in each group. This is research, not a treatment recommendation.
GastritisNot enough evidence
Too few or too small studies to know if it works.
Open the Gastritis pageKidney Disease (General)Not tested in people
Only tested in animals, cells or theory. Results like these often do not carry over to people.
All 3 studies with a clear result found a benefit.
In animal studies of diabetes-related kidney injury, Chaga reduced renal tubular damage scores and the area of collagen deposition. Biochemical, ultrasound, and tissue findings suggested effects that may delay progression of diabetic kidney disease.
Open the Kidney Disease (General) pageBreast CancerNot tested in people
Only tested in animals, cells or theory. Results like these often do not carry over to people.
The one study found a benefit.
Open the Breast Cancer pageCancer (General)Not tested in people
Only tested in animals, cells or theory. Results like these often do not carry over to people.
The one study found a benefit.
Open the Cancer (General) pageCOVID-19Not tested in people
Only tested in animals, cells or theory. Results like these often do not carry over to people.
The one study found a benefit.
Open the COVID-19 pageDiabetes Type 2Not tested in people
Only tested in animals, cells or theory. Results like these often do not carry over to people.
The one study found a benefit.
In animal research, Chaga showed blood-sugar- and blood-lipid-lowering effects alongside anti-inflammatory activity and improved the structure of some organs and cells. These findings indicate potential relevance to type 2 diabetes, but they do not establish the same effects in people.
Open the Diabetes Type 2 pageLung CancerNot tested in people
Only tested in animals, cells or theory. Results like these often do not carry over to people.
The one study found a benefit.
Open the Lung Cancer pageObesityNot tested in people
Only tested in animals, cells or theory. Results like these often do not carry over to people.
The one study found a benefit.
In high-fat-diet mice, Inonotus obliquus extracts improved body-weight growth rate, accumulated body-weight gain, and accumulated energy intake within 14 weeks. Its polysaccharide reduced body weight, systemic lipid accumulation, and obesity-related liver injury in mice.
Open the Obesity page
Before you try it
What studies and reports say about side effects and who it may not suit.
- Side effects
Possible: Kidney Function Decrease.
8 more with weak evidence.
- May not suit you if you have
- Bleeding Disorders, Chronic Kidney Disease, Kidney Stones, Organ Transplant Recipient, Pre-Surgery, Autoimmune Disease (General), and 4 more
- Pregnancy, breastfeeding, children
- Avoid in breastfeeding and children. Not enough data for pregnancy.
- Reported by users
- Anxiety Increase (12 posts) and Insomnia (6 posts)
General wellness information, not medical advice. Ask a doctor before you start, especially if you take medicines or have a health condition.
The expert view shows every study, dose protocol and source.
How it works
Chaga is described as a fungus containing beta-glucans and other polysaccharides. These compounds provide a proposed basis for immune-modulating activity, which helps connect findings related to immune and inflammatory responses rather than treating each reported effect as an unrelated action. Comparisons with other medicinal mushrooms focus on complementary polysaccharide profiles and the possibility of enhanced immune function, but this does not establish that every reported outcome arises through the same pathway.
Chaga is also described in relation to free-radical scavenging capacity. Vitamin C may potentiate this activity by regenerating oxidized antioxidants, providing a separate antioxidant rationale that may help explain findings grouped around protection from oxidative stress. However, the available mechanism descriptions do not identify a specific pathway linking Chaga to cognitive, mood, digestive, skin, or sleep-related experiences. Those reports therefore should not be assumed to share a confirmed biological mechanism with its proposed immune or antioxidant actions.
Some proposed combinations remain theoretical. In particular, there is no established evidence that Piperine (BioPerine) enhances the absorption of Chaga triterpenoids or polysaccharides, and the proposed interaction is described as biologically implausible for large polysaccharides without constituent-specific pharmacokinetic data.
Effects
19 listedStart here
The best we have, but the evidence is still weak
- →Antioxidant Protection EnhancementCertaintyLowSourceReference knowledgenot used for recommendations2 other sources
In laboratory testing, IO–AgNPs and MIO–AgNPs significantly outperformed native I. obliquus extract (p<0.05). This result comes from in vitro testing rather than a clinical outcome in people.
What the sources found
2 positive · 0 neutral · 0 negativeconfidence 70/100
How big is the effect
No study gave a number we could compare, so the size is not known.
Why this rating
Rests on: reports and reference sources, no studies
- No studies: low at most
- Not eligible as a recommendation: low at most
Where the evidence comes from
- Reference knowledge2
Dose & course
1–3 g daily of dried extract
Who it applies to
- Adults
Why it isn't used for recommendations
No oral-route evidence in adults
Open Antioxidant Protection EnhancementShow studies (2)
Reference knowledgepositive75% confidenceChaga is exceptionally rich in melanin and polyphenols, particularly superoxide dismutase (SOD)-like compounds and triterpenes, which are well-documented for potent free radical scavenging and systemic antioxidant effects.
1–3 g daily of dried extractweeks to monthsEstablished pharmacologyReference knowledgepositive65% confidenceChaga is rich in melanin, polyphenols, and superoxide dismutase, which scavenge free radicals and reduce oxidative stress.
1-2 g dailyEstablished pharmacology - →Blood Glucose Level SupportCertaintyLowSourceAnimal researchanimal / in-vitro onlylong-termnot adult-relevantnot used for recommendations8 cited studies
In diabetic animal models, IOPH lowered blood glucose by 31% versus the model (8.59 ± 1.55 vs 12.51 ± 1.3 mmol/L, p<0.01). In another model, PIO-30 lowered it to 10.1±3.2 versus 22.2±2.2 mmol/L with STZ (P<0.05), while PIO-20 and PIO-10 were not statistically significant.
What the sources found
7 positive · 1 neutral · 0 negativeconfidence 34/100
How big is the effect
No study gave a number we could compare, so the size is not known.
Why this rating
Rests on: animal or lab studies only
- Animal or lab studies only: low at most
- Not eligible as a recommendation: low at most
Who was studied
- People with a condition
- Chronic Kidney Disease
- Diabetes Type 2
- Kidney Disease (General)
- Obesity
Where the evidence comes from
- Article8
Dose & course
21 days
Who it applies to
- Animal
- Unspecified
Why it isn't used for recommendations
Animal or in-vitro evidence only
Open Blood Glucose Level SupportShow studies (8)
Animal studyDAnimalpositive35% confidence2021Significant reduction in blood glucose at 250 and 500 mg/kg (no numeric values reported in abstract)
Top journalAnimal studyDAnimalneutral35% confidence2020Neither IOE nor IOP improved HFD-induced impairment of glucose tolerance; no significant difference reported
Top journalNo control groupAnimal studyDAnimalpositive35% confidence2017Reduced fasting blood glucose (direction reported; numeric value not in abstract)
Top journalNo control groupAnimal studyDAnimalpositive35% confidence2024Improvement reported; no numerical values in abstract
No control groupAnimal studyDAnimalpositive35% confidence2026FBG decreased by 52.29% vs Model after 4 weeks (SWEPC-H, 300 mg/kg/day)
-52.29%Large effectWeak journalSome bias concerns+2 more in SourcesAnimal studyDAnimalpositive35% confidence2023EtCE-EA 300 and 500 mg/kg significantly lowered fasting blood glucose vs 1/3 NT + STZ alone (p<0.01); 100 mg/kg effect not reported as significant
Weak journalSome bias concerns - →Cholesterol Level ReductionCertaintyLowSourceAnimal researchanimal / in-vitro onlylong-termnot adult-relevantnot used for recommendations7 cited studies
In animal models, total cholesterol was lower with IOPH and IOPM than in the model group (3.34 ± 0.39 and 4.04 ± 0.25 vs 4.69 ± 0.39 mmol/L, p<0.05). HIOP produced a 40.0% reduction versus HFD (3.69 ± 0.60 vs 6.15 ± 0.54 mmol/L, p<0.05).
What the sources found
7 positive · 0 neutral · 0 negativeconfidence 34/100
How big is the effect
No study gave a number we could compare, so the size is not known.
Why this rating
Rests on: animal or lab studies only
- Animal or lab studies only: low at most
- Not eligible as a recommendation: low at most
Who was studied
- People with a condition
- Diabetes Type 2
- Dyslipidemia
- Kidney Disease (General)
- Obesity
Where the evidence comes from
- Article7
Dose & course
12 weeks
Who it applies to
- Animal
- Unspecified
Why it isn't used for recommendations
Animal or in-vitro evidence only
Open Cholesterol Level ReductionShow studies (7)
Animal studyDAnimalpositive35% confidence2024TC significantly lower than MG (p<0.05); no numeric values reported
Top journalSome bias concernsAnimal studyDAnimalpositive35% confidence2021Increased HDL-C and liver glycogen; decreased TC, TG and LDL-C at 250 and 500 mg/kg (no numeric values reported in abstract)
Top journalAnimal studyDAnimalpositive30% confidence2017Increased HDL-C; decreased TC, TG and LDL-C (numeric values not in abstract)
Top journalNo control groupAnimal studyDAnimalpositive35% confidence2024Improvement reported; no numerical values in abstract
No control groupAnimal studyDAnimalpositive35% confidence2026significant decrease in serum TG, TC and NEFA vs HFD (no numeric values reported)
Weak journalSome bias concerns+1 more in SourcesAnimal studyDAnimalpositive35% confidence2024Serum TC decreased in IO_H vs ORG (p=0.005); ORG elevated vs CON (p<0.001)
Weak journalSome bias concernsNo control group - →Kidney Health SupportCertaintyLowSourceAnimal researchanimal / in-vitro onlylong-termnot adult-relevantnot used for recommendations5 cited studies
At 17 weeks in an animal model of diabetic kidney disease, both doses significantly reduced SCr versus the DKD model (p<0.001); Chaga100 returned SCr to levels not different from the normal control. Kidney-related measures also significantly improved with IO_L and IO_H versus ORG (p<0.001) and were not different from CON.
What the sources found
4 positive · 1 neutral · 0 negativeconfidence 35/100
How big is the effect
No study gave a number we could compare, so the size is not known.
Why this rating
Rests on: animal or lab studies only
- Animal or lab studies only: low at most
- Not eligible as a recommendation: low at most
Who was studied
- People with a condition
- Chronic Kidney Disease
- Diabetes Type 2
- Kidney Disease (General)
Where the evidence comes from
- Article5
Dose & course
12 weeks
Who it applies to
- Animal
- Unspecified
Why it isn't used for recommendations
Animal or in-vitro evidence only
Open Kidney Health SupportShow studies (5)
Animal studyDAnimalneutral35% confidence2026Kidney Injury Induced by High-Dose Chaga Mushroom Consumption: Experimental Evidence in a Rat Model.
HD group had lowest serum Cr, significantly lower than control; authors attribute to glomerular hyperfiltration
Some bias concernsNo control groupAnimal studyDAnimalpositive35% confidence2024Improvement reported; no numerical values in abstract
No control groupAnimal studyDAnimalpositive35% confidence202424-h urinary protein significantly reduced in IO_H vs ORG at four time points from week 10 to week 20 (p<0.05)
Weak journalSome bias concernsNo control groupAnimal studyDAnimalpositive35% confidence2023EtCE-EA 300 mg/kg reduced ACR (p<0.05) and 500 mg/kg reduced ACR (p<0.01) vs 1/3 NT + STZ alone
Weak journalSome bias concernsAnimal studyDAnimalpositive35% confidence2016ACR significantly decreased with LIOP 1000 mg/kg vs saline at 8 weeks (p<0.05); no significant difference at 2 weeks; 300 mg/kg not significant
Weak journalSome bias concerns - →Insulin Sensitivity ImprovementCertaintyLowSourceAnimal researchanimal / in-vitro onlylong-termnot adult-relevantnot used for recommendations5 cited studies
What the sources found
5 positive · 0 neutral · 0 negativeconfidence 34/100
How big is the effect
No study gave a number we could compare, so the size is not known.
Why this rating
Rests on: animal or lab studies only
- Animal or lab studies only: low at most
- Not eligible as a recommendation: low at most
Who was studied
- People with a condition
- Diabetes Type 2
- Kidney Disease (General)
- Obesity
Where the evidence comes from
- Article5
Dose & course
8 weeks
Who it applies to
- Animal
- Unspecified
Why it isn't used for recommendations
Animal or in-vitro evidence only
Open Insulin Sensitivity ImprovementShow studies (5)
Animal studyDAnimalpositive35% confidence2021Significant alleviation at 250 and 500 mg/kg (no numeric values reported in abstract)
Top journalAnimal studyDAnimalpositive30% confidence2020Both IOE and IOP reduced the increase in fasting glucose difference induced by HFD; no numeric effect size reported
Top journalNo control group500 mg/kg/day (IOE); 1000 mg/kg/day (IOP)10 weeks (fasting glucose comparison within 14-week study)PMID 32685836Animal studyDAnimalpositive35% confidence2017Improved glucose tolerance (direction reported; numeric value not in abstract)
Top journalNo control groupAnimal studyDAnimalpositive35% confidence2026HOMA-IR decreased by 44.42% vs Model (abstract); SWEPC-H lower than SWEPC-L (p=0.001) and MET (p=0.022)
-44.42%Large effectWeak journalSome bias concernsAnimal studyDAnimalpositive35% confidence2016AUC significantly smaller in LIOP (300 and 1000 mg/kg) groups vs saline at 8 weeks; no significant difference at 4 weeks
Weak journalSome bias concerns - →Triglyceride Level ReductionCertaintyLowSourceAnimal researchanimal / in-vitro onlylong-termnot adult-relevantnot used for recommendations4 cited studies
In animal models, triglycerides fell to 2.23 ± 0.42, 2.53 ± 0.42, and 2.68 ± 0.31 mmol/L across IOPH, IOPM, and IOPL, versus 3.08 ± 0.22 mmol/L in the model group (all p<0.05). HIOP produced a 24.8% reduction versus HFD (2.37 ± 0.20 vs 3.15 ± 0.36 mmol/L, p<0.05).
What the sources found
4 positive · 0 neutral · 0 negativeconfidence 34/100
How big is the effect
No study gave a number we could compare, so the size is not known.
Why this rating
Rests on: animal or lab studies only
- Animal or lab studies only: low at most
- Not eligible as a recommendation: low at most
Who was studied
- People with a condition
- Dyslipidemia
- Kidney Disease (General)
- Obesity
Where the evidence comes from
- Article4
Dose & course
12 weeks
Who it applies to
- Animal
- Unspecified
Why it isn't used for recommendations
Animal or in-vitro evidence only
Open Triglyceride Level ReductionShow studies (4)
Animal studyDAnimalpositive35% confidence2024TG significantly lower than MG (p<0.05); no numeric values reported
Top journalSome bias concernsAnimal studyDAnimalpositive30% confidence2020Both IOE and IOP reduced HFD-induced hepatic triglyceride accumulation; no numeric effect size reported
Top journalNo control groupAnimal studyDAnimalpositive35% confidence2024Liver TG in ORG higher than IO_H (p=0.035); IO_H not different from CON
Weak journalSome bias concernsNo control groupAnimal studyDAnimalpositive35% confidence2016Triglycerides significantly reduced with LIOP 300 and 1000 mg/kg at 8 weeks (p<0.05 each); no significant effect at 4 weeks
Weak journalSome bias concerns - →Weight Management SupportCertaintyLowSourceAnimal researchanimal / in-vitro onlylong-termnot adult-relevantnot used for recommendations5 cited studies
In animals, body-weight gain was significantly reduced with IO_L and IO_H compared with ORG (p=0.029 and p<0.001, respectively).
What the sources found
3 positive · 2 neutral · 0 negativeconfidence 30/100
How big is the effect
No study gave a number we could compare, so the size is not known.
Why this rating
Rests on: animal or lab studies only
- Animal or lab studies only: low at most
- Not eligible as a recommendation: low at most
Who was studied
- People with a condition
- Diabetes Type 2
- Obesity
Where the evidence comes from
- Article5
Dose & course
2 weeks
Timing
felt within days · sustained
Who it applies to
- Animal
- Unspecified
Why it isn't used for recommendations
Animal or in-vitro evidence only
Open Weight Management SupportShow studies (5)
Animal studyDAnimalpositive25% confidence2022Attenuated body weight loss (no numeric data in abstract)
Top journalAnimal studyDAnimalpositive35% confidence2021IOE significantly lower accumulated BWG than IOP at week 2 (p = 0.0146); no effect size reported
Top journalSome bias concernsAnimal studyDAnimalneutral30% confidence2020IOE group had less energy intake than IOP group, p = 0.078 (not significant)
Top journalNo control groupAnimal studyDAnimalpositive35% confidence2026significant decline in body weight and weight gain rate vs HFD (no numeric values reported)
Weak journalSome bias concernsAnimal studyDAnimalneutral25% confidence2018No significant difference in body weight between sample groups and model group
Weak journal
Low probability(5)
- →Liver Health SupportCertaintyLowSourceAnimal researchanimal / in-vitro onlylong-termnot adult-relevantnot used for recommendations4 cited studies
In an animal model, the liver score was significantly lower versus the DB group (p<0.01), indicating reduced steatosis and fibrosis.
What the sources found
3 positive · 1 neutral · 0 negativeconfidence 29/100
How big is the effect
No study gave a number we could compare, so the size is not known.
Why this rating
Rests on: animal or lab studies only
- Animal or lab studies only: low at most
- Not eligible as a recommendation: low at most
Who was studied
- Diabetes Type 2
- Dyslipidemia
- Obesity
Where the evidence comes from
- Article4
Dose & course
13 weeks
Who it applies to
- Animal
- Unspecified
Why it isn't used for recommendations
Animal or in-vitro evidence only
Open Liver Health SupportShow studies (4)
Animal studyDAnimalpositive35% confidence2024Reduced area and severity of steatosis qualitatively; no quantification reported
Top journalSome bias concernsAnimal studyDAnimalpositive35% confidence2026reduced hepatic lipid droplets, gWAT lipid accumulation and adipocyte size vs HFD (qualitative histology; no numeric values reported)
Weak journalSome bias concernsAnimal studyDAnimalneutral17% confidence2022Evaluation of Toxicity and Efficacy of Inotodiol as an Anti-Inflammatory Agent Using Animal Model.
No elevations in AST, ALT or bilirubin versus vehicle; no significant liver damage on histology or Ishak score
Weak journalSome bias concernsAnimal studyDAnimalpositive30% confidence2022Colonic score extremely significantly lower (p<0.001); liver score lower (p<0.01); renal score lower (p<0.05) vs DB
Weak journalHigh risk of bias - →Body Composition ImprovementCertaintyLowSourceAnimal researchanimal / in-vitro onlylong-termnot adult-relevantnot used for recommendations4 cited studies
What the sources found
3 positive · 1 neutral · 0 negativeconfidence 28/100
How big is the effect
No study gave a number we could compare, so the size is not known.
Why this rating
Rests on: animal or lab studies only
- Animal or lab studies only: low at most
- Not eligible as a recommendation: low at most
Who was studied
- Healthy people and patients
- Diabetes Type 2
Where the evidence comes from
- Article4
Dose & course
12 weeks
Who it applies to
- Animal
- Unspecified
Why it isn't used for recommendations
Animal or in-vitro evidence only
Open Body Composition ImprovementShow studies (4)
Animal studyDAnimalpositive35% confidence2024BWG significantly reduced in IO_H vs ORG (p<0.001); IO_L also reduced (p=0.029)
Weak journalSome bias concernsNo control groupAnimal studyDAnimalpositive30% confidence2022IO-1× 241 ± 2, IO-2× 230 ± 2, IO-3× 227 ± 3 mm² vs vehicle 189 ± 3 mm²; group p-value not reported
Weak journalSome bias concernsAnimal studyDAnimalneutral17% confidence2022Evaluation of Toxicity and Efficacy of Inotodiol as an Anti-Inflammatory Agent Using Animal Model.
No significant difference from vehicle at weeks 4, 8 and 13
Weak journalSome bias concernsAnimal studyDAnimalpositive30% confidence2022IO mice lighter than DB at week 8; no effect size reported
Weak journalHigh risk of bias - →HDL Cholesterol IncreaseCertaintyLowSourceAnimal researchanimal / in-vitro onlynot adult-relevantnot used for recommendations2 cited studies
In animal models, HDL was 0.77 ± 0.22 mmol/L with IOPH versus 0.35 ± 0.09 mmol/L in the model, while HIOP produced a 49.2% increase versus HFD (2.76 ± 0.37 vs 1.85 ± 0.14 mmol/L).
What the sources found
2 positive · 0 neutral · 0 negativeconfidence 35/100
How big is the effect
No study gave a number we could compare, so the size is not known.
Why this rating
Rests on: animal or lab studies only
- Animal or lab studies only: low at most
- Not eligible as a recommendation: low at most
Who was studied
- People with a condition
- Dyslipidemia
- Kidney Disease (General)
Where the evidence comes from
- Article2
Dose & course
8 weeks
Who it applies to
- Animal
- Unspecified
Why it isn't used for recommendations
Animal or in-vitro evidence only
Open HDL Cholesterol IncreaseShow studies (2)
Animal studyDAnimalpositive35% confidence2024HDL-C significantly higher than MG (p<0.05); no numeric values reported
Top journalSome bias concernsAnimal studyDAnimalpositive35% confidence2016HDL/LDL ratio significantly elevated with LIOP 300 and 1000 mg/kg at 8 weeks (p<0.05 and p<0.01)
Weak journalSome bias concerns - →Neuroprotective EffectCertaintyLowSourceAnimal researchanimal / in-vitro onlynot adult-relevantnot used for recommendations2 cited studies
What the sources found
2 positive · 0 neutral · 0 negativeconfidence 30/100
How big is the effect
No study gave a number we could compare, so the size is not known.
Why this rating
Rests on: animal or lab studies only
- Animal or lab studies only: low at most
- Not eligible as a recommendation: low at most
Who was studied
- People with a condition
- Alzheimers Disease
Where the evidence comes from
- Article2
Dose & course
15 days
Who it applies to
- Animal
- In vitro
- Unspecified
Why it isn't used for recommendations
Animal or in-vitro evidence only
Open Neuroprotective EffectShow studies (2)
Animal studyDAnimalpositive35% confidence2023Positive Aβ42 staining lighter and sparser in IOP group vs Ctrl; metformin showed a similar reduction (P < 0.001)
Some bias concernsIn vitroDIn vitropositive25% confidence2021attenuated apoptosis (no numeric value in abstract)
not reportedPMID 34591398 - →Inflammation ReductionCertaintyLowSourceTheoreticalnot used for recommendations1 cited study · 2 other sources
In animal models, TNF-α decreased with IO_L and IO_H versus ORG, with a dose-dependent effect (p<0.05); it also significantly decreased versus DB (p<0.01).
What the sources found
2 positive · 0 neutral · 1 negativeconfidence 42/100
How big is the effect
No study gave a number we could compare, so the size is not known.
Why this rating
Rests on: reports and reference sources, no studies
- No studies: low at most
- Not eligible as a recommendation: low at most
Who was studied
- Diabetes Type 2
Where the evidence comes from
- Article1
- Community reports1
- Reference knowledge1
Dose & course
1-2 g daily · 8 weeks
Timing
short-lived
Who it applies to
- Adults
- Unspecified
Why it isn't used for recommendations
The result was negative
Open Inflammation ReductionShow studies (3)
Animal studyDAnimalnegative30% confidence2022TNF-α and IL-1β considerably decreased vs DB (p<0.01); IL-6 decreased (p<0.05); IL-10 increased (p<0.001)
Weak journalHigh risk of biasReference knowledgepositive60% confidenceChaga's triterpenoids and polysaccharides inhibit pro-inflammatory cytokines and COX-2, providing anti-inflammatory effects.
1-2 g dailyWeeksEstablished pharmacologyCommunity reportsmoderate effectpositive35% confidenceThis effect was mentioned in 4 of 229 Reddit reports discussing it.
4 mentionsReddit 4sustained
Very low probability(7)
- →DNA Damage ProtectionCertaintyVery lowSourceReference knowledgelong-termnot used for recommendations1 other source
What the sources found
1 positive · 0 neutral · 0 negativeconfidence 65/100
How big is the effect
No study gave a number we could compare, so the size is not known.
Why this rating
Rests on: reports and reference sources, no studies
- No studies: low at most
- Not eligible as a recommendation: low at most
Where the evidence comes from
- Reference knowledge1
Who it applies to
- Adults
Why it isn't used for recommendations
Very little evidence on file
Open DNA Damage ProtectionShow studies (1)
Reference knowledgepositive65% confidenceChaga's high content of betulinic acid and polysaccharides has demonstrated radioprotective and DNA-stabilizing effects in vitro and in animal models, reducing oxidative DNA strand breaks.
Established pharmacology - →Immune System SupportCertaintyVery lowSourceAnimal researchnot used for recommendations1 cited study · 2 other sources
Chaga contains beta-glucans and polysaccharides described as modulating immune cell activity and cytokine production. It is also described as an immunomodulatory medicinal mushroom with beta-glucans that enhance immune function.
What the sources found
3 positive · 0 neutral · 0 negativeconfidence 52/100
How big is the effect
No study gave a number we could compare, so the size is not known.
Why this rating
Rests on: animal or lab studies only
- Animal or lab studies only: low at most
- Not eligible as a recommendation: low at most
Who was studied
- Healthy people
Where the evidence comes from
- Article1
- Community reports1
- Reference knowledge1
Dose & course
1–2 g daily · Temporal monitoring 0 to 35 days post-inoculation
Timing
short-lived
Who it applies to
- Adults
- Animal
- Unspecified
Why it isn't used for recommendations
Very little evidence on file
Open Immune System SupportShow studies (3)
Animal studyDAnimalpositive35% confidence2018Significantly enhanced vs control group; superior to APS (0.2% diet) positive control; numeric values not reported in abstract
Weak journal0.8% of diet for 7 days before each immunizationTemporal monitoring 0 to 35 days post-inoculationPMID 30227259Reference knowledgepositive70% confidenceBeta-glucans in Chaga, especially (1→3)-β-D-glucans, are established immunomodulators that enhance macrophage and natural killer (NK) cell activity via dectin-1 and complement receptor pathways.
1–2 g dailychronic useEstablished pharmacologyCommunity reportsmoderate effectpositive50% confidenceThis effect was mentioned in 17 of 313 community reports discussing it (Reddit 12, YouTube 3, Bluesky 2).
17 mentionsReddit 12 · Youtube 3 · Bluesky 2felt within weekssustained - →Cognitive Function ImprovementCertaintyVery lowSourceAnimal researchnot used for recommendations1 cited study · 2 other sources
What the sources found
3 positive · 0 neutral · 0 negativeconfidence 28/100
How big is the effect
No study gave a number we could compare, so the size is not known.
Why this rating
Rests on: animal or lab studies only
- Animal or lab studies only: low at most
- Not eligible as a recommendation: low at most
Where the evidence comes from
- Community reports2
- Article1
Dose & course
not-reported
Timing
short-lived
Who it applies to
- Adults
- Animal
- Isolated
- Unspecified
Why it isn't used for recommendations
Very little evidence on file
Open Cognitive Function ImprovementShow studies (3)
Animal studyDAnimalpositive25% confidence2025Marked amelioration of cognitive impairment (no numeric values reported in abstract)
Community reportsmoderate effectpositive35% confidenceThis effect was mentioned in 4 of 229 Reddit reports discussing it.
4 mentionsReddit 4felt within weeksbuilds up over timeCommunity reportsmoderate effectpositive25% confidenceThis effect was mentioned in 2 of 229 Reddit reports discussing it.
2 mentionsReddit 2felt immediatelyshort-lived - →Physical Endurance IncreaseCertaintyVery lowSourceAnimal researchanimal / in-vitro onlynot adult-relevantnot used for recommendations1 cited study
What the sources found
1 positive · 0 neutral · 0 negativeconfidence 35/100
How big is the effect
No study gave a number we could compare, so the size is not known.
Why this rating
Rests on: animal or lab studies only
- Animal or lab studies only: low at most
- Not eligible as a recommendation: low at most
Who was studied
- Healthy people
Where the evidence comes from
- Article1
Dose & course
6 weeks
Who it applies to
- Animal
- Unspecified
Why it isn't used for recommendations
Very little evidence on file
Open Physical Endurance IncreaseShow studies (1)
Animal studyDAnimalpositive35% confidence202243.0 ± 19.2 min vs 10.4 ± 3.7 min; 4.12-fold, p=0.0005; dose trend p<0.0001
MD 32.6Weak journalSome bias concerns - →Fatty Liver PreventionCertaintyVery lowSourceAnimal researchanimal / in-vitro onlynot adult-relevantnot used for recommendations1 cited study
An animal model showed markedly reduced steatosis, with fewer and smaller fat vacuoles and less hepatocyte swelling than in the model group.
What the sources found
1 positive · 0 neutral · 0 negativeconfidence 35/100
How big is the effect
No study gave a number we could compare, so the size is not known.
Why this rating
Rests on: animal or lab studies only
- Animal or lab studies only: low at most
- Not eligible as a recommendation: low at most
Who was studied
- Fatty Liver Nafld
Where the evidence comes from
- Article1
Who it applies to
- Animal
- Unspecified
Why it isn't used for recommendations
Very little evidence on file
Open Fatty Liver PreventionShow studies (1)
Animal studyDAnimalpositive35% confidence2022Remarkable amelioration of lipid accumulation (no numeric values in abstract)
Top journalNo control group - →Physical Strength IncreaseCertaintyVery lowSourceAnimal researchanimal / in-vitro onlynot adult-relevantnot used for recommendations1 cited study
What the sources found
1 positive · 0 neutral · 0 negativeconfidence 30/100
How big is the effect
No study gave a number we could compare, so the size is not known.
Why this rating
Rests on: animal or lab studies only
- Animal or lab studies only: low at most
- Not eligible as a recommendation: low at most
Who was studied
- Healthy people
Where the evidence comes from
- Article1
Dose & course
6 weeks
Who it applies to
- Animal
- Unspecified
Why it isn't used for recommendations
Very little evidence on file
Open Physical Strength IncreaseShow studies (1)
Animal studyDAnimalpositive30% confidence2022288.3 ± 80.4 g vs 206.9 ± 69.5 g; 1.39-fold, p=0.0029; dose trend p=0.0067
MD 81.4Weak journalSome bias concerns - →Gut Microbiome Health SupportCertaintyVery lowSourceAnimal researchanimal / in-vitro onlynot adult-relevantnot used for recommendations1 cited study
What the sources found
1 positive · 0 neutral · 0 negativeconfidence 25/100
How big is the effect
No study gave a number we could compare, so the size is not known.
Why this rating
Rests on: animal or lab studies only
- Animal or lab studies only: low at most
- Not eligible as a recommendation: low at most
Who was studied
- Diabetes Type 2
Where the evidence comes from
- Article1
Dose & course
8 weeks
Who it applies to
- Animal
- Unspecified
Why it isn't used for recommendations
Very little evidence on file
Open Gut Microbiome Health SupportShow studies (1)
Animal studyDAnimalpositive25% confidence2022Concentrations increased vs DB; no effect size reported
Weak journalHigh risk of bias
Conditions it's used for
Complaints and diagnoses people take it for8 listedThe best we have, but the evidence is still weak
- →Kidney Disease (General)CertaintyLowSourceAnimal researchnot used for recommendations3 cited studies
In animal studies of diabetes-related kidney injury, Chaga reduced renal tubular damage scores and the area of collagen deposition. Biochemical, ultrasound, and tissue findings suggested effects that may delay progression of diabetic kidney disease.
How big is the effect
No study gave a number we could compare, so the size is not known.
Why this rating
Rests on: animal or lab studies only
- Animal or lab studies only: low at most
Who was studied
- People with a condition
Why it isn't used for recommendations
Animal or in-vitro evidence only
Subsumes: chronic_kidney_disease
Open Kidney Disease (General)Show studies (3)
Animal studyDAnimal35% confidence2024This research supports the potential application of Chaga in the clinical prevention and treatment of T2DM and diabetic nephropathy (DN)
No control groupAnimal studyDAnimal35% confidence2025Our findings suggest that Chaga may represent a promising candidate for renal fibrosis treatment, though further experimental validation is needed
Weak journalAnimal studyDAnimal35% confidence2021we confirmed that chaga had pharmacodynamic effects on diabetes-induced kidney injury
Weak journal
Very low probability(7)
- →GastritisCertaintyVery lowSourceReference knowledgenot used for recommendations1 other source
How big is the effect
No study gave a number we could compare, so the size is not known.
Why this rating
Rests on: reports and reference sources, no studies
- No studies: low at most
Where the evidence comes from
- Reference knowledge
Why it isn't used for recommendations
Too little evidence to judge
Open GastritisShow studies (1)
Reference knowledge50% confidenceTraditionally used to soothe gastric mucosa and reduce inflammation in gastritis; preclinical data support gastroprotective effects.
- →Breast CancerCertaintyVery lowSourceAnimal researchnot used for recommendations1 cited study
How big is the effect
No study gave a number we could compare, so the size is not known.
Why this rating
Rests on: animal or lab studies only
- Animal or lab studies only: low at most
Who was studied
- People with a condition
Why it isn't used for recommendations
Very little evidence on file
Open Breast CancerShow studies (1)
Animal studyDAnimal35% confidence2024[Anti-tumor effect of Inonotus obliquus extract on 4T1 tumor-bearing mice].
Inonotus obliquus extract can inhibit tumor growth to some extent, and the mechanism may be related to the inhibition of cyclin expression.
- →Cancer (General)CertaintyVery lowSourceAnimal researchnot used for recommendations1 cited study
How big is the effect
No study gave a number we could compare, so the size is not known.
Why this rating
Rests on: animal or lab studies only
- Animal or lab studies only: low at most
Why it isn't used for recommendations
Very little evidence on file
Open Cancer (General)Show studies (1)
Animal studyDAnimal30% confidence2025This study investigated the effect of an aqueous extract of Inonotus obliquus (IOAE) against diethyl-nitrosamine/carbon tetrachloride (DEN/CCl 4 ) induced HCC in mice
No control group - →COVID-19CertaintyVery lowSourceAnimal researchnot used for recommendations1 cited study
How big is the effect
No study gave a number we could compare, so the size is not known.
Why this rating
Rests on: animal or lab studies only
- Animal or lab studies only: low at most
Why it isn't used for recommendations
Very little evidence on file
Open COVID-19Show studies (1)
Animal studyDAnimal35% confidence2023The results obtained indicate the possibility of using basidial fungus Inonotus obliquus aqueous extract as a preventive agent against circulating variants of SARS-CoV-2 virus.
No control group - →Diabetes Type 2CertaintyVery lowSourceAnimal researchnot used for recommendations1 cited study
In animal research, Chaga showed blood-sugar- and blood-lipid-lowering effects alongside anti-inflammatory activity and improved the structure of some organs and cells. These findings indicate potential relevance to type 2 diabetes, but they do not establish the same effects in people.
How big is the effect
No study gave a number we could compare, so the size is not known.
Why this rating
Rests on: animal or lab studies only
- Animal or lab studies only: low at most
Who was studied
- People with a condition
Why it isn't used for recommendations
Very little evidence on file
Open Diabetes Type 2Show studies (1)
Animal studyDAnimal35% confidence2024This research supports the potential application of Chaga in the clinical prevention and treatment of T2DM and diabetic nephropathy (DN)
No control group - →Lung CancerCertaintyVery lowSourceAnimal researchnot used for recommendations1 cited study
How big is the effect
No study gave a number we could compare, so the size is not known.
Why this rating
Rests on: animal or lab studies only
- Animal or lab studies only: low at most
Why it isn't used for recommendations
Very little evidence on file
Open Lung CancerShow studies (1)
Animal studyDAnimal30% confidence2026explore the potential anti-tumor mechanisms of Inonotus obliquus polysaccharides (IOPs) against non-small cell lung cancer (NSCLC)
Top journal - →ObesityCertaintyVery lowSourceAnimal researchnot used for recommendations1 cited study
In high-fat-diet mice, Inonotus obliquus extracts improved body-weight growth rate, accumulated body-weight gain, and accumulated energy intake within 14 weeks. Its polysaccharide reduced body weight, systemic lipid accumulation, and obesity-related liver injury in mice.
How big is the effect
No study gave a number we could compare, so the size is not known.
Why this rating
Rests on: animal or lab studies only
- Animal or lab studies only: low at most
Who was studied
- People with a condition
Why it isn't used for recommendations
Very little evidence on file
Open ObesityShow studies (1)
Animal studyDAnimal30% confidence2021Both Inonotus obliquus extracts significantly improved the body weight growth rate, accumulated BWG, and accumulated EI of HFD mice within 14 weeks.
Top journal
Side effects
9 listedHighest probability
- →Kidney Function DecreaseCertaintyMediumSourceClinical3 cited studies · 2 other sources
An acute case of oxalate nephropathy with nephrotic syndrome has been reported after Chaga use.
What the sources found
0 not observed · 0 unclear · 5 reportedconfidence 42/100
How big is the effect
No study gave a number we could compare, so the size is not known.
Who was studied
- People with a condition
- Acute Kidney Injury
- Chronic Kidney Disease
Where the evidence comes from
- Article3
- Community reports1
- Reference knowledge1
Dose & course
16 weeks
Open Kidney Function DecreaseShow studies (5)
Case reportDnegativen=145% confidence2022Acute kidney injury with calcium oxalate crystal deposition and nephrotic syndrome features
No control groupCase reportDnegativen=145% confidence2020End-stage renal disease with oxalate nephropathy
No control groupAnimal studyDAnimalnegative35% confidence2026Kidney Injury Induced by High-Dose Chaga Mushroom Consumption: Experimental Evidence in a Rat Model.
Significantly higher in HD group than other groups
Some bias concernsNo control groupReference knowledgenegative65% confidenceChaga accumulates high levels of oxalates; chronic use may lead to oxalate nephropathy and progressive decline in glomerular filtration rate.
Community reportsnegative20% confidenceThis effect was mentioned in 2 of 51 YouTube videos discussing it.
Youtube 2
Low probability(8)
- →Heavy Metal AccumulationCertaintyLowSourceReference knowledge1 other source
Chaga mushrooms can bioaccumulate cadmium, lead, and mercury from birch tree substrate, so long-term use of wild-harvested Chaga may lead to toxic metal exposure.
What the sources found
0 not observed · 0 unclear · 1 reportedconfidence 60/100
How big is the effect
No study gave a number we could compare, so the size is not known.
Where the evidence comes from
- Reference knowledge1
Open Heavy Metal AccumulationShow studies (1)
Reference knowledgenegative60% confidenceChaga grows on birch trees that absorb environmental toxins; wild-harvested specimens may contain elevated levels of cesium, strontium, or other heavy metals, posing risk with long-term use.
- →Kidney Stone Formation RiskCertaintyLowSourceReference knowledge1 other source
Some Chaga preparations contain very high oxalate levels, which can increase urinary oxalate and promote calcium oxalate crystallization, kidney stones, or oxalate nephropathy.
What the sources found
0 not observed · 0 unclear · 1 reportedconfidence 60/100
How big is the effect
No study gave a number we could compare, so the size is not known.
Where the evidence comes from
- Reference knowledge1
Open Kidney Stone Formation RiskShow studies (1)
Reference knowledgenegative60% confidenceChaga's high oxalate content can promote calcium oxalate kidney stone formation, especially with prolonged high-dose use.
- →Allergic ReactionCertaintyLowSourceReference knowledge1 other source
As a mushroom product, Chaga can trigger allergic reactions in people with mushroom allergies.
What the sources found
0 not observed · 0 unclear · 1 reportedconfidence 55/100
How big is the effect
No study gave a number we could compare, so the size is not known.
Where the evidence comes from
- Reference knowledge1
Open Allergic ReactionShow studies (1)
Reference knowledgenegative55% confidenceAs a fungus, Chaga may trigger allergic reactions in individuals sensitive to mushrooms or molds, ranging from mild to severe.
- →Blood Sugar DecreaseCertaintyLowSourceReference knowledge1 other source
Chaga may lower blood glucose levels, potentially causing hypoglycemic symptoms in susceptible individuals.
What the sources found
0 not observed · 0 unclear · 1 reportedconfidence 55/100
How big is the effect
No study gave a number we could compare, so the size is not known.
Where the evidence comes from
- Reference knowledge1
Open Blood Sugar DecreaseShow studies (1)
Reference knowledgenegative55% confidenceChaga may lower blood glucose levels, potentially causing hypoglycemia, especially at high doses or with fasting.
- →Blood ThinningCertaintyLowSourceReference knowledge1 other source
Chaga has anticoagulant properties that may increase the tendency to bleed and bruise.
What the sources found
0 not observed · 0 unclear · 1 reportedconfidence 55/100
How big is the effect
No study gave a number we could compare, so the size is not known.
Where the evidence comes from
- Reference knowledge1
Open Blood ThinningShow studies (1)
Reference knowledgenegative55% confidenceChaga exhibits antiplatelet activity, which may prolong bleeding time and increase bruising.
- →Nutrient MalabsorptionCertaintyLowSourceReference knowledge1 other source
At high or prolonged powder doses, Chaga’s oxalate content can bind calcium and other divalent minerals in the gut. Clinically meaningful depletion at typical tea doses has not been demonstrated.
What the sources found
0 not observed · 0 unclear · 1 reportedconfidence 50/100
How big is the effect
No study gave a number we could compare, so the size is not known.
Where the evidence comes from
- Reference knowledge1
Open Nutrient MalabsorptionShow studies (1)
Reference knowledgenegative50% confidenceHigh tannin content in Chaga may bind dietary minerals (iron, zinc, calcium), reducing gastrointestinal absorption and potentially contributing to deficiencies with chronic use.
- →Inflammation IncreaseCertaintyLowSourceAnimal research1 cited study · 1 other source
What the sources found
0 not observed · 0 unclear · 2 reportedconfidence 40/100
How big is the effect
No study gave a number we could compare, so the size is not known.
Where the evidence comes from
- Article1
- Community reports1
Dose & course
16 weeks
Open Inflammation IncreaseShow studies (2)
Animal studyDAnimalnegative35% confidence2026Kidney Injury Induced by High-Dose Chaga Mushroom Consumption: Experimental Evidence in a Rat Model.
Significantly elevated in HD group vs other groups
Some bias concernsNo control groupCommunity reportsnegative45% confidenceParadoxical increase in joint pain and systemic inflammation reported by some users at high doses, possibly due to overstimulation of immune cytokines (e.g., TNF-α, IL-6).
- →Injury Risk IncreaseCertaintyLowSourceAnimal research1 cited study
What the sources found
0 not observed · 0 unclear · 1 reportedconfidence 30/100
How big is the effect
No study gave a number we could compare, so the size is not known.
Where the evidence comes from
- Article1
Dose & course
16 weeks
Open Injury Risk IncreaseShow studies (1)
Animal studyDAnimalnegative30% confidence2026Kidney Injury Induced by High-Dose Chaga Mushroom Consumption: Experimental Evidence in a Rat Model.
TUNEL 43.7 ± 3.5 vs 8.4 ± 1.6 mm2/10^4 (control); Bcl-2 25.6% vs 48.6% (control)
Some bias concernsNo control group
Don't take it if
Conditions and states that rule it out10 listedHighest probability
- →Bleeding DisordersCertaintyLowSourceReference knowledgeTheoretical
Chaga's anticoagulant effects may increase hemorrhage risk in people with bleeding disorders.
Where the evidence comes from
- Reference knowledge
Confidence
confidence 75/100
Open Bleeding DisordersRationale
Due to Chaga’s potential anticoagulant and antiplatelet effects from triterpenoids and polyphenols, it may exacerbate bleeding in individuals with coagulopathies such as hemophilia or von Willebrand disease.
- →Chronic Kidney DiseaseCertaintyLowSourceReference knowledgeTheoretical
Chaga can contain very high oxalate concentrations, and prolonged or high-dose intake has caused oxalate nephropathy. Reduced renal clearance increases this risk.
Where the evidence comes from
- Reference knowledge
Confidence
confidence 75/100
Open Chronic Kidney DiseaseRationale
High oxalate content may worsen kidney function and increase stone risk.
- →Kidney StonesCertaintyLowSourceReference knowledgeTheoretical
Where the evidence comes from
- Reference knowledge
Confidence
confidence 75/100
Open Kidney StonesRationale
High oxalate content increases the risk of calcium oxalate stone formation; contraindicated in those with a history of kidney stones.
- →Organ Transplant RecipientCertaintyLowSourceReference knowledgeTheoretical
Immune-stimulating constituents may oppose anti-rejection therapy. Clinical relevance is uncertain, but graft rejection is a high-consequence potential harm.
Where the evidence comes from
- Reference knowledge
Confidence
confidence 75/100
Open Organ Transplant RecipientRationale
Chaga’s immune-stimulating beta-glucans may counteract immunosuppressive therapy and increase risk of graft rejection in organ transplant recipients.
- →Pre-SurgeryCertaintyLowSourceReference knowledgeTheoretical
Chaga should be discontinued before surgery because of bleeding risk; typically 2 weeks prior is recommended.
Where the evidence comes from
- Reference knowledge
Confidence
confidence 75/100
Open Pre-SurgeryRationale
Antiplatelet effects may increase bleeding risk during surgery.
- →Autoimmune Disease (General)CertaintyLowSourceReference knowledgeTheoretical
Chaga's immune-stimulating properties may exacerbate autoimmune conditions by increasing immune activity.
Where the evidence comes from
- Reference knowledge
Confidence
confidence 70/100
Open Autoimmune Disease (General)Rationale
Chaga’s immune-stimulating beta-glucans may exacerbate conditions like lupus, rheumatoid arthritis, or multiple sclerosis by enhancing Th1 and macrophage activity.
- →BreastfeedingCertaintyLowSourceReference knowledgeTheoretical
Safety data for Chaga use during breastfeeding are insufficient, and compounds may transfer to the infant.
Where the evidence comes from
- Reference knowledge
Confidence
confidence 70/100
Open BreastfeedingRationale
No safety data in lactation; potential transfer of bioactive compounds to the infant warrants avoidance.
Low probability(3)
- →PediatricCertaintyLowSourceReference knowledgeTheoretical
No safety data are available for children. Immature metabolic and renal systems may be more susceptible to oxalate accumulation and immune modulation effects.
Where the evidence comes from
- Reference knowledge
Confidence
confidence 70/100
Open PediatricRationale
Safety not established; risk of oxalate nephropathy in developing kidneys.
- →PregnancyCertaintyLowSourceReference knowledgeTheoretical
Safety data for Chaga use during pregnancy are insufficient, and its immunomodulatory effects pose a theoretical risk.
Where the evidence comes from
- Reference knowledge
Confidence
confidence 70/100
Open PregnancyRationale
Safety during pregnancy has not been established; due to lack of data and potential immunomodulatory effects, use should be avoided.
- →Acute Kidney InjuryCertaintyLowSourceTheoretical1 cited study
Chaga mushroom-induced oxalate nephropathy has clinically manifested as nephrotic syndrome.
How big is the effect
No study gave a number we could compare, so the size is not known.
Who was studied
- People with a condition
Rationale
ingesting high doses of Chaga mushroom can cause acute oxalate nephropathy
Open Acute Kidney InjuryShow studies (1)
Case reportDn=125% confidence2022ingesting high doses of Chaga mushroom can cause acute oxalate nephropathy
No control group
Pregnancy, breastfeeding and children
What is known for each group. Ask a doctor before using it in any of them.
- PregnancyNot enough data
Too little research to say anything. This is not a clearance.
Safety during pregnancy has not been established; due to lack of data and potential immunomodulatory effects, use should be avoided.
- BreastfeedingAvoid
Studies or guidelines say to avoid it in this group.
No safety data in lactation; potential transfer of bioactive compounds to the infant warrants avoidance.
- ChildrenAvoid
Studies or guidelines say to avoid it in this group.
Safety not established; risk of oxalate nephropathy in developing kidneys.
Interactions
Combine with caution
Highest severity first
- →SulfonylureasTheoreticalModerate
Chaga may lower blood glucose, so combining it with sulfonylureas could produce an additive effect and increase the risk of hypoglycemia.
- →WarfarinTheoreticalCaution
Chaga may theoretically increase bleeding risk with warfarin, but a specific CYP2C9 interaction and clinically documented elevation in INR have not been established.
- →InsulinTheoreticalCaution
Chaga may be a potentially dangerous combination with insulin; consult a healthcare provider before combining them.
- →Antiplatelet AgentsTheoreticalCaution
Chaga inhibits platelet aggregation, so combining it with antiplatelet agents may increase bleeding risk.
- →PhenytoinTheoreticalCaution
Theoretical concern that Chaga may increase phenytoin levels and risk of toxicity; clinically significant interaction is not established.
- →Statins (HMG-CoA Reductase Inhibitors)TheoreticalCaution
Theoretical concern that Chaga may increase statin levels and risk of myopathy; clinically significant interaction is not established.
Where the evidence comes from
- Reference knowledge
Open Statins (HMG-CoA Reductase Inhibitors)Confidence
confidence 50/100
Okay to combine with
Highest probability of useful synergy
- →SupplementsQuercetinCertaintyMediumSourceReference knowledgePotentiating
Quercetin enhances bioavailability of fungal polyphenols via inhibition of COMT and glucuronidation; may increase plasma concentration and half-life of Chaga’s active constituents.
- →SupplementsVitamin DCertaintyMediumSourceReference knowledgeComplementary
Vitamin D and Chaga both support innate immunity via modulation of dendritic cells and T-reg differentiation; their effects on immune homeostasis are complementary.
- →SupplementsMaitakeCertaintyMediumSourceReference knowledgeComplementary
Both Chaga and Maitake are medicinal mushrooms rich in beta-glucans, and their complementary polysaccharide profiles may enhance immune function together.
- →SupplementsShiitakeCertaintyMediumSourceReference knowledgeComplementary
Shiitake's lentinan and Chaga's polysaccharides may synergistically stimulate innate immune responses.
- →SupplementsTurkey TailCertaintyMediumSourceReference knowledgeComplementary
Turkey tail's PSK/PSP and Chaga's beta-glucans may provide additive immunomodulatory and antioxidant effects.
- →SupplementsVitamin C (Ascorbic Acid)CertaintyMediumSourceReference knowledgeComplementary
Vitamin C may regenerate oxidized antioxidants, potentially strengthening Chaga’s free-radical-scavenging capacity.
Where the evidence comes from
- Reference knowledge
Open Vitamin C (Ascorbic Acid)Confidence
confidence 60/100
- →SupplementsReishiCertaintyMediumSourceReference knowledgeAdditive
Both contain immunomodulatory polysaccharides; combined use may enhance immune support.
Medium probability(2)
- →SupplementsZincCertaintyMediumSourceReference knowledgeAdditive
Zinc is a cofactor for superoxide dismutase and supports immune cell signaling; synergizes with Chaga’s beta-glucan-mediated immune modulation to enhance NK cell activity and cytokine balance.
- →SupplementsOmega-3CertaintyMediumSourceTheoreticalAdditive
Omega-3s and Chaga both reduce pro-inflammatory cytokines (e.g., IL-6, TNF-α); their combined use may have additive anti-inflammatory effects, particularly in chronic inflammatory states.
Weakens or is weakened by
Highest probability
- →SupplementsActivated CharcoalCertaintyMediumSourceReference knowledgeCompetitive
Activated charcoal adsorbs large-molecule beta-glucans and polyphenols in the gut, reducing intestinal absorption and bioavailability of Chaga’s active constituents.
- →Immunosuppressants (Anti-Rejection)CertaintyMediumSourceReference knowledgeCompetitive
Chaga's immune-stimulating properties may reduce the intended immunosuppressive effect, potentially compromising treatment efficacy.
Where the evidence comes from
- Reference knowledge
Open Immunosuppressants (Anti-Rejection)Confidence
confidence 60/100
- →SupplementsMagnesiumCertaintyMediumSourceReference knowledgeRatio-dependent
Chaga contains oxalates which can bind to magnesium, reducing its absorption.
- →SupplementsDietary Fiber (Prebiotics)CertaintyMediumSourceReference knowledgeCompetitive
Psyllium forms a viscous gel in the GI tract that may physically impede absorption of Chaga’s high-molecular-weight polysaccharides, reducing immunomodulatory efficacy.
Where the evidence comes from
- Reference knowledge
Open Dietary Fiber (Prebiotics)Confidence
confidence 55/100
Unrated(2)
- →CyclosporineCompetitive
Theoretical concern that Chaga's immunostimulant effects may reduce cyclosporine efficacy; clinically significant interaction is not established.
- →TacrolimusCompetitive
Theoretical concern that Chaga's immunostimulant effects may reduce tacrolimus efficacy; clinically significant interaction is not established.
Forms & dosage
Chaga
Oral5/10
- Bioavailability
- Low
- Availability
- Health & supplement stores
- Rating
- 5/10 · Minimal
Traditional form with minimal processing; requires hot-water extraction to release beta-glucans, so raw powder has poor bioavailability of key polysaccharides.
May contain chitin, which can be hard to digest for some individuals.
Chaga Hot Water Extract
Oral7/10
This form has a milder taste than dual extracts and may suit people who avoid alcohol-based tinctures.
- Bioavailability
- Moderate
- Availability
- Health & supplement stores
- Rating
- 7/10 · Moderate
The most studied and widely used form; hot-water extraction solubilizes immunomodulating beta-glucans, making them bioavailable, unlike raw powder.
Well-tolerated; the standard form for immune support.
Chaga Dual Extract (Water + Alcohol)
Oral8/10
This form may have a strong, bitter taste. Liquid extracts can be added to hot water or taken directly.
- Bioavailability
- High
- Availability
- Health & supplement stores
- Rating
- 8/10 · Minimal
Captures both polysaccharides (water-soluble) and triterpenoids like betulinic acid (alcohol-soluble), offering a broader phytochemical profile than water-only extracts.
Alcohol-based tinctures may not suit everyone; glycerite alternatives exist.
Chaga Fermented Extract
Oral6/10
- Bioavailability
- High
- Availability
- Health & supplement stores
- Rating
- 6/10 · Minimal
Fermentation may pre-digest chitin and enhance bioavailability of secondary metabolites, but research is sparse compared to hot-water extracts.
May offer additional probiotic benefits; taste can be strong.
Chaga Tea Bags
Oral4/10
- Bioavailability
- Low
- Availability
- Health & supplement stores
- Rating
- 4/10 · Minimal
Convenient but typically a short steep, yielding lower polysaccharide extraction than a prolonged decoction of chunks or powder.
Mild, earthy taste; a gentle introduction to chaga.
Chaga Chunks (Dried Sclerotium)
Oral5/10
- Bioavailability
- Low
- Availability
- Health & supplement stores
- Rating
- 5/10 · Minimal
Requires long simmering (1-4 hours) to extract beneficial compounds; more labor-intensive but yields a traditional full-spectrum decoction.
Can be re-used for multiple brews until color fades.
Research & prescription forms (1)
Forms used in research or medicine — not everyday consumer products.
Inonotus obliquus Polysaccharide Extract (Parenteral)
IntravenousClinical (injected)prescription · research only
Investigational IV formulation used in a few clinical studies for cancer and immune modulation; not available as a consumer product.
High-molecular-weight polysaccharides isolated for injection; studied in oncology settings.
Community experience
Based on 318 public posts from Reddit, YouTube, Bluesky, Longecity, and Hacker News.
What users report (not studied)
No study backs these. They come only from public posts and videos.
12 outcomes mentioned across 318 public reports. A report often mentions several, so these counts do not add up to the total.
Reported benefits7
- Mood Improvement23 mentionsReddit, Youtube
- Physical Energy Increase21 mentionsReddit, Youtube
- Concentration Improvement14 mentionsReddit
- Brain Fog Reduction11 mentionsReddit
- Anxiety Reduction10 mentionsReddit
- Sleep Quality Improvement9 mentionsReddit, Youtube
- Skin Health Improvement8 mentionsReddit, Youtube
Reported side effects5
- Anxiety Increase12 mentionsReddit
- Insomnia6 mentionsReddit
- Diarrhea
- Gastric Irritation
- Hepatotoxicity (Liver Toxicity)
What people report taking
dose read from 42 of 318 reports- Median
- 250 mg
- Common range
- 100-500 mg
- Reported range
- 50–2,000 mg
Forms taken
How often
Self-reported from public posts and videos. Not evidence of effect, and not a recommendation.
More
Write-up
For self-tracking, record Body Weight in kg under consistent conditions and compare it again after 4 weeks. Its movement is conflicting, so a change in either direction should not be treated as a clear sign of success or failure. An unchanged result is still information rather than a verdict.
The other markers require clinical testing. After 4 weeks, Fasting Glucose is expected to decrease. After 8 weeks, HDL Cholesterol is expected to increase, while Total Cholesterol, Triglycerides, and LDL Cholesterol are expected to decrease. After 5 weeks, Creatinine, Aspartate Aminotransferase, and Albumin-to-Creatinine Ratio are expected to decrease. After 2 weeks, Blood Urea Nitrogen is expected to remain unchanged; this is not a sign of success or failure.
Annual Checkup Basic can provide several of these measurements in one fasting assessment, including Aspartate Aminotransferase, Creatinine, Fasting Glucose, HDL Cholesterol, LDL Cholesterol, Total Cholesterol, and Triglycerides. It does not replace separate consideration of the other markers.
These directions should be interpreted cautiously because the best study design listed for the markers is a study in animals. An unchanged marker is information, not a diagnosis or a reason by itself to conclude that Chaga has or has not worked. Any abnormal result should be discussed with a clinician.
References
90 screened · 79 analysed · 88 listed below
Studies and sources cited on this page. Evidence quality varies — check the grade on each.
- Chaga Mushroom (Inonotus obliquus) Attenuates DNCB-Induced Atopic Dermatitis by Modulating Oxidative Stress and Cytokine Expression.J Microbiol Biotechnol2026Animal studyD
- Inonotus obliquus Polysaccharides Prevent High-Fat Diet-Induced Obesity in Mice Related to Reshaping Gut Microbiota.Foods2026Animal studyD
- Kidney Injury Induced by High-Dose Chaga Mushroom Consumption: Experimental Evidence in a Rat Model.J Korean Med Sci2026Animal studyD
- Inonotus obliquus Crude Melanin Ameliorates DSS-Induced Colitis with Modulation of Gut Microbiota and Neutrophil pro-NETotic Activation.Nutrients2026Animal studyD
- The effects of polysaccharides from Inonotus obliquus, artemisinin, and dihydroartemisinin on the reproductive system of male mice infected with Neospora caninum.Front Vet Sci2026Animal studyD
- Neutral Inonotus obliquus polysaccharide (IOP-W): Structural characterization and p53/MAPK-mediated apoptotic activity against pancreatic Cancer unveiled through multi-omics.Int J Biol Macromol2026Animal studyD
- Anti-NSCLC mechanism of Inonotus obliquus polysaccharides revealed by combined metabolomics and proteomics.Int J Biol Macromol2026Animal studyD
- Inonotus obliquus (Ach. ex Pers.) Pilát aqueous extract alleviates acute cold exposure/rewarming-induced myocardial injury by regulating mitochondrial dynamics via liver kinase B1/adenosine monophosphate-activated protein kinase/peroxisome proliferator-activated receptor gamma coactivator-1 alpha signaling pathway activation.J Ethnopharmacol2026Animal studyD
- Effects of dietary Inonotus obliquus fermentation product supplementation on growth performance, immune function, blood glucose level, and gut microbiota in cats.Front Vet Sci2026Animal studyD
- Dietary 3,4-Dihydroxybenzalacetone alleviates LPS-induced intestinal injury in Leizhou black ducks by improving mitochondrial function and suppressing apoptosis.Poult Sci2026Animal studyD
Show all 88 references
- Supernatant of Water Extraction-Ethanol Precipitation of Chaga mushroom Improves Hyperglycemia in Type 2 Diabetes Mellitus and Is Accompanied by Changes in Gut Microbiota Composition.2026Animal studyD
- A Novel Acidic Polysaccharide from Inonotus obliquus (IOP-1) Suppresses Growth and Induces Apoptosis in Non-Small Cell Lung Cancer both In Vitro and In Vivo.2026Animal studyD
- Green Extraction and Liposomal Encapsulation of Inonotus obliquus (Chaga) Extracts: Comparative Phytochemical and Antioxidant Analysis.2026In vitroD
- Elucidating the Anti-Diabetic Mechanisms of Mushroom Chaga (Inonotus obliquus) by Integrating LC-MS, Network Pharmacology, Molecular Docking, and Bioinformatics.2025OtherD
- Integrating Network Pharmacology and Experimental Validation to Explore the Effect and Mechanism of Inonotus obliquus Polysaccharide in the Treatment of Rheumatoid Arthritis.2025Animal studyD
- Inonotus obliquus fermentation product improves growth performance and meat quality probably through intestine and antioxidant capacity enhanced by gut microbes and metabolites regulation in rabbits.2025Animal studyD
- Inonotus obliquus (chaga) ameliorates folic acid-induced renal fibrosis in mice: the crosstalk analysis among PT cells, macrophages and T cells based on single-cell sequencing.2025Animal studyD
- INO10, a Chaga Mushroom Extract, Alleviates Alzheimer's Disease-Related Pathology and Cognitive Deficits in 3xTg-AD Mice.2025Animal studyD
- Triterpenoids from the edible mushroom Inonotus obliquus attenuates cognitive impairment in vitro and in vivo.2025Animal studyD
- Mitigation of experimental hepatocellular Carcinoma by Inonotus obliquus Mushroom extract in association with oxidative stress and inflammation signaling.2025Animal studyD
- Effects of dietary Inonotus obliquus fermentation products supplementation on meat quality and antioxidant capacity of finishing pigs2025Animal studyD
- Design and Evaluation of a Inonotus obliquus-AgNP-Maltodextrin Delivery System: Antioxidant, Antimicrobial, Acetylcholinesterase Inhibitory and Cytotoxic Potential.2025In vitroD
- Betulinic acid from Inonotus obliquus ameliorates T2DM by modulating short-chain fatty acids producing bacteria and amino acids metabolism in db/db mice.2025Animal studyD
- The aqueous extracts of Inonotus obliquus (Chaga) augment host defense against Listeria monocytogenes infection.2025Animal studyD
- Effects of Inonotus obliquus on ameliorating podocyte injury in ORG mice through TNF pathway and prediction of active compounds.2024Animal studyD
- Chaga mushroom extract suppresses oral cancer cell growth via inhibition of energy metabolism.2024In vitroD
- Study of active components and mechanisms mediating the hypolipidemic effect of Inonotus obliquus polysaccharides.2024Animal studyD
- Antidiabetic activity of Inonotus obliquus water extract in alloxan-induced diabetic mice.2024Animal studyD
- [Anti-tumor effect of Inonotus obliquus extract on 4T1 tumor-bearing mice].2024Animal studyD
- Inonotus obliquus (Chaga) against HFD/STZ-induced glucolipid metabolism disorders and abnormal renal functions by regulating NOS-cGMP-PDE5 signaling pathway.2024Animal studyD
- Protective effect of Inonotus obliquus polysaccharide on mice infected with Neospora caninum.2024Animal studyD
- Structural analysis of polysaccharide from Inonotus obliquus and investigate combined impact on the sex hormones, intestinal microbiota and metabolism in SPF male mice.2024Animal studyD
- Liver-X receptor β-selective agonist CE9A215 regulates Alzheimer’s disease- associated pathology in a 3xTg-AD mouse model2024Animal studyD
- Anti-cancer activity of Chaga mushroom (Inonotus obliquus) against dog bladder cancer organoids.2023Animal studyD
- Inonotus obliquus polysaccharide are linear molecules that alter the abundance and composition of intestinal microbiota in Sprague Dawley rats.2023Animal studyD
- Renoprotective Impacts of Inonotus obliquus Ethanol-Ethyl Acetate Extract on Combined Streptozotocin and Unilateral Nephrectomy-Induced Diabetic Nephropathy in Mice.2023Animal studyD
- Raw Inonotus obliquus polysaccharide counteracts Alzheimer's disease in a transgenic mouse model by activating the ubiquitin-proteosome system.2023Animal studyD
- [Antiviral activity of basidial fungus Inonotus obliquus aqueous extract against SARS-CоV-2 virus (Coronaviridae: Betacoronavirus: Sarbecovirus) in vivo in BALB/c mice model].2023Animal studyD
- Polysaccharide from fermented mycelium of Inonotus obliquus attenuates the ulcerative colitis and adjusts the gut microbiota in mice.2023Animal studyD
- Study on the hypolipidemic effect of Inonotus obliquus polysaccharide in hyperlipidemia rats based on the regulation of intestinal flora.2023Animal studyD
- Inonotus obliquus upregulates muscle regeneration and augments function through muscle oxidative metabolism2023Animal studyD
- In Vitro Immunomodulatory Effects of Inonotus obliquus Extracts on Resting M0 Macrophages and LPS-Induced M1 Macrophages.2022In vitroD
- Inonotus obliquus aqueous extract prevents histopathological alterations in liver induced by environmental toxicant Microcystin.2022Animal studyD
- Methanol extract of Inonotus obliquus improves type 2 diabetes mellitus through modifying intestinal flora.2022Animal studyD
- Chaga mushroom-induced oxalate nephropathy that clinically manifested as nephrotic syndrome: A case report.2022Case reportDn=1
- Effect of Inonotus obliquus Extract Supplementation on Endurance Exercise and Energy-Consuming Processes through Lipid Transport in Mice.2022Animal studyD
- Anti-diabetic effects of Inonotus obliquus extract in high fat diet combined streptozotocin-induced type 2 diabetic mice.2022Animal studyD
- Polysaccharide derived from Inonotus obliquus inhibits lipopolysaccharide-induced acute endometritis in mice.2022Animal studyD
- Triterpenoid acids from medicinal mushroom Inonotus obliquus (Chaga) alleviate hyperuricemia and inflammation in hyperuricemic mice: Possible inhibitory effects on xanthine oxidase activity2022Animal studyD
- Evaluation of Toxicity and Efficacy of Inotodiol as an Anti-Inflammatory Agent Using Animal Model.2022Animal studyD
- A polysaccharide from Inonotus obliquus ameliorates intestinal barrier dysfunction in mice with type 2 diabetes mellitus.2022Animal studyD
- Inonotus obliquus and its bioactive compounds alleviate non-alcoholic fatty liver disease via regulating FXR/SHP/SREBP-1c axis.2022Animal studyD
- Triterpenoid acids from medicinal mushroom Inonotus obliquus (Chaga) alleviate hyperuricemia and inflammation in hyperuricemic mice: Possible inhibitory effects on xanthine oxidase activity.2022Animal studyD
- Inonotus obliquus polysaccharide ameliorates serum profiling in STZ-induced diabetic mice model.2021Animal studyD
- Lipid-Lowering Effects of Inonotus obliquus Polysaccharide In Vivo and In Vitro.2021Animal studyD
- Renal Protective Effects of Inonotus obliquus on High-Fat Diet/Streptozotocin-Induced Diabetic Kidney Disease Rats: Biochemical, Color Doppler Ultrasound and Histopathological Evidence.2021Animal studyD
- The difference of regulatory effect of two Inonotus obliquus extracts on high-fat diet mice in relation to the fatty acid elongation function of gut microbiota.2021Animal studyD
- Chaga mushroom (Inonotus obliquus) polysaccharides exhibit genoprotective effects in UVB-exposed embryonic zebrafish (Danio rerio) through coordinated expression of DNA repair genes.2021Animal studyD
- Protective Effects of Chaga Medicinal Mushroom, Inonotus obliquus (Agaricomycetes), Extract on β-Amyloid-Induced Neurotoxicity in PC12 Cells and Aging Rats: In Vitro and In Vivo Studies.2021In vitroD
- Effect of Inonotus obliquus (Fr.) Pilat extract on the regulation of glycolipid metabolism via PI3K/Akt and AMPK/ACC pathways in mice.2021Animal studyD
- Effect of Inonotus obliquus polysaccharide on composition of the intestinal flora in mice with acute endometritis.2021Animal studyD
- Molecular insights and cell cycle assessment upon exposure to Chaga (Inonotus obliquus) mushroom polysaccharides in zebrafish (Danio rerio).2020Animal studyD
- Genoprotective effects of Chaga mushroom ( Inonotus obliquus ) polysaccharides in UVB-exposed embryonic zebrafish ( Danio rerio ) through coordinated expression of DNA repair genes2020Animal studyD
- Anti-allergic effect of inotodiol, a lanostane triterpenoid from Chaga mushroom, via selective inhibition of mast cell function.2020Animal studyD
- Inonotus obliquus polysaccharide protects against adverse pregnancy caused by Toxoplasma gondii infection through regulating Th17/Treg balance via TLR4/NF-κB pathway.2020Animal studyD
- Spatial structure and anti-fatigue of polysaccharide from Inonotus obliquus.2020Animal studyD
- Inonotus obliquus polysaccharide ameliorates impaired reproductive function caused by Toxoplasma gondii infection in male mice via regulating Nrf2-PI3K/AKT pathway.2020Animal studyD
- Inonotus obliquus Polysaccharide Ameliorates Azoxymethane/Dextran Sulfate Sodium-Induced Colitis-Associated Cancer in Mice via Activation of the NLRP3 Inflammasome.2020Animal studyD
- Cecal Butyrate (Not Propionate) Was Connected with Metabolism-Related Chemicals of Mice, Based on the Different Effects of the Two Inonotus obliquus Extracts on Obesity and Their Mechanisms.2020Animal studyD
- Development of End Stage Renal Disease after Long-Term Ingestion of Chaga Mushroom: Case Report and Review of Literature.2020Case StudyDn=1
- Inonotus obliquus attenuates histamine-induced microvascular inflammation.2019Animal studyD
- Assessment of the Gastroprotective Effect of the Chaga Medicinal Mushroom, Inonotus obliquus (Agaricomycetes), Against the Gastric Mucosal Ulceration Induced by Ethanol in Experimental Rats.2019Animal studyD
- Inonotus obliquus polysaccharide ameliorates dextran sulphate sodium induced colitis involving modulation of Th1/Th2 and Th17/Treg balance.2019Animal studyD
- The polysaccharide from Inonotus obliquus protects mice from Toxoplasma gondii-induced liver injury.2019Animal studyD
- Structure Characterization and Hypoglycaemic Activities of Two Polysaccharides from Inonotus obliquus.2018Animal studyD
- Immunopotentiating effect of Inonotus obliquus fermentation products administered at vaccination in chickens.2018Animal studyD
- Actions of Inonotus obliquus against Hyperuricemia through XOD and Bioactives Screened by Molecular Modeling.2018Animal studyD
- Inonotus obliquus polysaccharide regulates gut microbiota of chronic pancreatitis in mice.2017Animal studyD
- Antidiabetic activities of polysaccharides separated from Inonotus obliquus via the modulation of oxidative stress in mice with streptozotocin-induced diabetes.2017Animal studyD
- Anti-diabetic effects of Inonotus obliquus polysaccharides in streptozotocin-induced type 2 diabetic mice and potential mechanism via PI3K-Akt signal pathway.2017Animal studyD
- Continuous intake of the Chaga mushroom (Inonotus obliquus) aqueous extract suppresses cancer progression and maintains body temperature in mice.2016Animal studyD
- Antioxidant activity of Inonotus obliquus polysaccharide and its amelioration for chronic pancreatitis in mice.2016Animal studyD
- Renal Protective Effects of Low Molecular Weight of Inonotus obliquus Polysaccharide (LIOP) on HFD/STZ-Induced Nephropathy in Mice.2016Animal studyD
- Purification, characterization and biological activity of a novel polysaccharide from Inonotus obliquus.2015Animal studyD
- Protective Effect of Polysaccharides from Inonotus obliquus on Streptozotocin-Induced Diabetic Symptoms and Their Potential Mechanisms in Rats.2014Animal studyD
- Anticancer activity of subfractions containing pure compounds of Chaga mushroom (Inonotus obliquus) extract in human cancer cells and in Balbc/c mice bearing Sarcoma-180 cells.2010Animal studyD
- Anti-inflammatory effects of Inonotus obliquus in colitis induced by dextran sodium sulfate.2010Animal studyD
- Established pharmacology